Saiyi Hengwei

Beijing Lingde Pharmaceutical Group (hereinafter referred to as Lingde Pharmaceutical) is a contract research organization (CRO) specializing in providing professional services for the entire clinical trial process for pharmaceutical and device companies. Lingde Pharmaceutical is committed to providing high-quality clinical trial services for clients while reducing R&D risks and saving R&D costs, thereby advancing the marketization process of products. Wang Zhifeng, general manager of the company, participated in meetings such as the project review of 5 research projects of the Beijing Municipal Science and Technology Commission. Meanwhile, Lingde Pharmaceutical is also the secretary-general unit of the Zhongguancun Zhongbang Medical Device Technology Innovation Alliance, and Saiyi Hengwei (Beijing) Medical Technology Co., Ltd. is a member of the Changping District Enterprise Confederation and Enterprise Credit Promotion Association. Lingde Pharmaceutical is headquartered in Beijing and has 3 subsidiaries, namely Beijing Lingde Pharmaceutical Technology Co., Ltd. (mainly undertaking drug registration and clinical services), Saiyi Hengwei (Beijing) Medical Technology Co., Ltd. (mainly undertaking device registration and clinical services), and Haishengen Beijing Medical Technology Co., Ltd. The company has 17 offices in major cities across the country, with more than 320 full-time employees, currently possessing resources of more than 300 institutional hospitals and more than 200 non-institutional tertiary Grade A hospitals, as well as resources of more than 100 experts in various clinical therapeutic fields. Corporate philosophy: Beijing Lingde Pharmaceutical Group always adheres to the corporate philosophy of being a "most trustworthy CRO company", building the most trustworthy service platform in China's pharmaceutical clinical field, continuously enhancing the company's professional value, cherishing every cooperation opportunity, and striving to provide clients with value-added user experience. Business scope and service content: The company's main business scope includes drug registration and clinical trials (CRO), clinical trial site management services (SMO), third-party quality control (AUDIT), prescription drug-to-OTC conversion, and post-marketing re-evaluation, etc., providing comprehensive one-stop services in all aspects such as registration, review, and clinical trial management. It promises that the qualifications of all cooperative research units and personnel comply with GCP and other laws and regulations, and that all clinical trial data submitted to sponsors are authentic, reliable, and traceable. Projects have passed the on-site clinical trial inspections of the State Food and Drug Administration and local FDAs. Since its establishment, it has undertaken more than 100 projects and has rich research experience in fields such as ophthalmology, cardiovascular, nuclear medicine, oncology, dentistry, pediatrics, and gynecology. Company website: *